DBV Technologies to Participate in Upcoming Investor Conference

Rhea-AI Summary

DBV Technologies has announced its participation in the SBV Securities Global Biopharma Conference from February 13 to 16, 2023. The company's CEO, Daniel Tassé, will present on February 16 and will also engage in one-on-one investor meetings throughout the day. A live webcast of the presentation can be accessed via the company's website, and a replay will be available for 90 days post-event. DBV Technologies focuses on Viaskin™, an innovative platform for immunotherapy aiming to treat food allergies with ongoing trials for Viaskin Peanut. The company is headquartered in Montrouge, France, and its shares trade under the ticker DBVT on Nasdaq.

Montrouge, France, February 10, 2023

DBV Technologies to Participate in Upcoming Investor Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the virtual SBV Securities Global Biopharma Conference taking place February 13 – 16, 2023. Daniel Tassé, Chief Executive Officer, will make a company presentation on Thursday, February 16, 2023, as well as participate in one-on-one investor meetings throughout the day.

A live webcast of the presentation will be available on the Investors & Media section of the Company’s website:   https://wsw.com/webcast/svb8/dbvt/1621296.

A replay will also be available on DBV Technologies’ website for 90 days after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Viaskin and EPIT are trademarks of DBV Technologies.

Attachment

• PDF Version

FAQ

What is DBV Technologies' participation in the SBV Securities Global Biopharma Conference?

DBV Technologies is participating in the SBV Securities Global Biopharma Conference from February 13 to 16, 2023.

When will DBV Technologies' CEO present at the conference?

Daniel Tassé, the CEO of DBV Technologies, will present on February 16, 2023.

Where can I watch DBV Technologies' conference presentation?

The live presentation will be available on the Investors & Media section of DBV Technologies' website.

Will there be a replay of DBV Technologies' presentation?

Yes, a replay of the presentation will be available for 90 days after the event.

What is the focus of DBV Technologies' Viaskin™ platform?

Viaskin™ is an investigational platform for immunotherapy aimed at treating food allergies.

What ticker symbol does DBV Technologies use on Nasdaq?

DBV Technologies trades under the ticker symbol DBVT on the Nasdaq.